Squarepoint
CERE

Squarepoint’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Squarepoint’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-446,018
Closed -$18.2M – 4845
2024
Q2 		$18.2M Buy
446,018
+354,333
+386% +$14.8M 0.03% 629
2024
Q1 		$3.88M Buy
91,685
+9,494
+12% +$399K 0.01% 1643
2023
Q4 		$3.48M Buy
82,191
+57,327
+231% +$1.65M 0.01% 1629
2023
Q3 		$543K Buy
+24,864
New +$622K ﹤0.01% 2746
2023
Q2 		– Sell
-32,300
Closed -$788K – 4131
2023
Q1 		$788K Sell
32,300
-21,504
-40% -$631K ﹤0.01% 2045
2022
Q4 		$1.7M Sell
53,804
-18,740
-26% -$529K 0.01% 1462
2022
Q3 		$2.05M Buy
+72,544
New +$2.16M 0.01% 1306
2022
Q2 		– Sell
-9,403
Closed -$329K – 3522
2022
Q1 		$329K Buy
9,403
+264
+3% +$7.71K ﹤0.01% 2233
2021
Q4 		$296K Sell
9,139
-66,248
-88% -$2.34M ﹤0.01% 2458
2021
Q3 		$2.22M Buy
+75,387
New +$2.12M 0.01% 1152

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Squarepoint's CERE Position: Q3 2024 in Review

Squarepoint sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 446,018 shares — an estimated $18.2M sold.

Squarepoint first reported a position in CERE in Q3 2021 and held it in 10 quarters. The position peaked at $18.2M in Q2 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Squarepoint reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Squarepoint sold 446,018 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $18.2M.
  • Squarepoint first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2021 and held it in 10 quarters.
  • Squarepoint's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $18.2M in Q2 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Squarepoint's 13F filing for Q3 2024, filed 14 Nov 2024.